Sandoz launches generic version of BENET® Tablets / ACTONEL® Tab in Japan
Tokyo, Japan, June 21, 2013 – Sandoz today announces the National Health Insurance price listing and launch in Japan of sodium risedronate tablets 2.5mg/17.5 mg [Sandoz], the generic version of BENET® Tablets / ACTONEL® Tab.
Sodium risedronate tablets 2.5mg/17.5 mg are indicated for the treatment of osteoporosis.
“Sandoz is proud to launch this important generic medicine, which further strengthens Sandoz’s leadership position in the primary care business,” said Junichi Nakamichi, Country Head of Sandoz Japan. “With this launch, Sandoz provides patients and health care professionals with an even broader range of high-quality, affordable treatment options,” he said.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry Sandoz offers a broad range of about 1,100 high-quality, affordable products that are no longer protected by patents. With nearly 26,000 employees in approximately 140 countries, Sandoz holds the #1 position globally in biosimilars, injectables, ophthalmics and dermatology as well as a strong global #5 position in inhalables. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances and anti -infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion.
Sandoz is on Twitter. Sign up to follow @Sandoz_Global at http://twitter.com/Sandoz_Global.